Cytokinetics | CYTK - Ordinary Share Capital


Cytokinetics reported $138.76M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Amgen USD 541M 0 Sep/2026
Arca Biopharma USD 50.17M 1.45M Mar/2026
Bayer EUR 982.42M 0 Sep/2026
Biogen USD 146.7M 200K Sep/2025
Brainstorm Cell Therapeutics USD 11.04M 0 Mar/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Cytokinetics USD 138.76M 14.33M Jun/2026
Eisai JPY 282.46M 0 Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 244.68M 4.21M Sep/2026
Geron USD 640.9M 2.54M Mar/2026
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 1.05M Jun/2026
Novartis USD 1.89B 12.09M Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026